hero image

Adam Koppel, Executive Vice President, Strategy and Business Development, to Return to Bain Capital

April 29, 2016 Corporate

Cambridge, Mass. – Biogen (NASDAQ: BIIB)  today announced that Adam Koppel, M.D., Ph.D., executive vice president, strategy and business development, will depart the company on June 2, 2016, to return to Bain Capital. 

Dr. Koppel joined Biogen as Chief Strategy Officer in 2014.  He is returning to Bain Capital, his previous employer, as a managing director on an initiative that will focus on delivering growth capital through private investments to companies in the biotech and life sciences sector.

“Adam has made important contributions during his tenure at Biogen, and we will miss him as a strategic thinker and colleague.  He brought a unique and valuable perspective to our business, and was instrumental in helping us to define our long-term strategic plan,” said George Scangos, Ph.D., chief executive officer.  “I wish Adam great success in his new role.”

“It has been an incredible learning experience to have been a part of Biogen during such a dynamic time in the organization’s history,” said Dr. Koppel. “I am honored to have worked with a team so committed to driving innovation and making a difference in the lives of patients, and I am proud of the progress we have made.   As I prepare to move back to Bain Capital, I am certain that Biogen will continue to be successful in advancing important new therapies.”

With Dr. Koppel’s departure, the Corporate Strategy, Business Development and Mergers and Acquisition functions will be led by Dr. Scangos, Dr. Michael Ehlers, executive vice president, research and development, and Paul Clancy, executive vice president, chief financial officer, respectively. 

About Biogen

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases.  Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies.  For more information, please visit www.biogen.com.  Follow us on Twitter.

Contact:

MEDIA CONTACT:

Todd Cooper
+1 781.464.3260
public.affairs@biogen.com

INVESTOR CONTACT:

Benjamin Strain
+1 781.464.2442
IR@biogen.com

thumb
February 6, 2023
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to treat major depressive disorder (MDD) and postpartum depression (PPD) Depression is a public health issue with significant unmet medical need CAMBRIDGE, Mass., Feb.

thumb
January 29, 2023
Lecanemab Receives Priority Review Status in Japan

TOKYO and CAMBRIDGE, Mass., Jan. 29, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that an application for